Abstract
Targeting anti-HER-2 therapy, trastuzumab, Lapatinib, T-DM1, and Pertuzumab is a standard therapy for HER-2-overexpressing breast cancer. But there are less data available related to anti-HER-2 therapy in elderly patients because they have been consistently underrepresented in clinical trials. Anti- HER-2 therapy among an elderly population was reviewed including approaches for making treatment effective.
MeSH terms
-
Aged
-
Antineoplastic Agents / therapeutic use
-
Breast Neoplasms* / drug therapy
-
Breast Neoplasms* / genetics
-
Breast Neoplasms* / metabolism
-
DNA, Neoplasm / genetics
-
Female
-
Gene Expression Regulation, Neoplastic / drug effects
-
Humans
-
Receptor, ErbB-2 / antagonists & inhibitors*
-
Receptor, ErbB-2 / biosynthesis
-
Receptor, ErbB-2 / genetics
-
Trastuzumab / therapeutic use*
-
Treatment Outcome
Substances
-
Antineoplastic Agents
-
DNA, Neoplasm
-
ERBB2 protein, human
-
Receptor, ErbB-2
-
Trastuzumab